LncRNA Taurine Upregulated Gene 1 as a Potential Biomarker in the Clinicopathology and Prognosis of Multiple Malignant Tumors: A Meta-Analysis

Table 1

Characteristics summary of the 57 eligible studies in this meta-analysis.

Study	Year	Origin of population	Cancer type	Sample number	lncRNA TUG1 high/low	Stage	Detection method	Study endpoints	Hazard ratios	NOS
S-h Guo	2020	China	NSCLC	132	52/80	I-IV	qRT-PCR	OS	K-M	6
N El-Khazragy	2020	Egypt	OC	100	50/50	I-IV	qRT-PCR	OS/PFS	K-M	6
G Jin	2020	China	ESCC	50	27/23	I-IV	qRT-PCR	OS	K-M	6
D-h Xiu	2020	China	PCa	50	25/25	I-IV	qRT-PCR	OS	K-M	7
Y-h Hao	2020	China	GC	110	80/30	I-IV	qRT-PCR	OS	K-M	8
J-b Zhong	2020	China	GC	83	49/34	I-IV	qRT-PCR	OS	HR	7
Y-n Xu	2020	China	NSCLC	79	45/34	I-IV	qRT-PCR	OS	K-M	8
X-z Chen	2020	China	PCa	54	16/38	I-IV	qRT-PCR	OS/PFS	HR/K-M	8
Y Xia	2020	China	CC	137	69/68	I-II	qRT-PCR	OS	HR/K-M	8
X-d Lu	2020	China	BC	90	52/38	I-III	qRT-PCR	OS	HR/K-M	8
Z-f Wang	2020	TCGA	ESCC	86	72/14	NA	RNA-seq	OS	K-M	6
L-z Gu	2020	China	OC	41	21/20	II-IV	qRT-PCR	OS	K-M	6
J Yang	2019	China	BLC	68	38/30	II-IV	qRT-PCR	OS	HR/K-M	8
X-r Lv	2019	China	EC	58	37/21	I-IV	qRT-PCR	OS	HR/K-M	8
Q Li	2019	China	AML	36	18/18	NA	qRT-PCR	OS	K-M	7
Y-q Wang	2019	China	Melanoma	40	NA	NA	qRT-PCR	OS	HR/K-M	5
B-q Hui	2019	China	PC	42	21/21	I-IV	qRT-PCR	OS	K-M	8
G Yu	2019	China	BLC	87	44/43	NA	qRT-PCR	OS	K-M	6
X-l Yang	2019	China	PCa	46	23/23	NA	qRT-PCR	DFS	K-M	6
T Xu	2019	China	PCa	70	35/35	I-IV	qRT-PCR	OS	K-M	7
M Wang	2019	China	CRC	124	62/62	II-III	qRT-PCR	RFS	K-M	8
H Zhou	2019	TCGA	HCC	371	91/274	NA	RNA-seq	OS	K-M	5
H Zhou	2019	TCGA	Melanoma	459	115/344	NA	RNA-seq	OS	K-M	5
H Zhou	2019	TCGA	OSA	259	65/194	NA	RNA-seq	OS	K-M	5
H Zhou	2019	TCGA	RCC	287	73/214	NA	RNA-seq	OS	K-M	5
H Zhou	2019	TCGA	BLC	406	102/304	NA	RNA-seq	OS	K-M	5
H Zhou	2019	TCGA	CRC	279	69/210	NA	RNA-seq	OS	K-M	5
H Zhou	2019	TCGA	GC	392	93/299	NA	RNA-seq	OS	K-M	5
H Zhou	2019	TCGA	BC (triple negative)	1081	273/808	NA	RNA-seq	OS	K-M	5
Y Zhang	2019	China	GC	85	48/37	I-IV	qRT-PCR	OS	K-M	7
W Wang	2018	China	GBM	51	NA	NA	RNA-seq	OS	HR	5
X-f Wang	2018	China	AML	186	93/93	NA	qRT-PCR	OS/EFS	HR/K-M	7
T-h Li	2018	China	OC	96	NA	I-IV	qRT-PCR	OS	HR/K-M	7
Q-l Wang	2018	China	OSA	94	47/47	IIA/IIB-III	qRT-PCR	OS	HR/K-M	8
C-h Xiao	2018	China	CRC	90	45/45	I-IV	qRT-PCR	OS/DFS	K-M	7
W-f Luo	2018	China	AML	73	NA	NA	qRT-PCR	OS	HR/K-M	6
J Qin	2018	China	AML	236	NA	NA	qRT-PCR	OS/EFS	HR/K-M	6
C-h Xu	2018	China	ESCC	42	21/21	NA	qRT-PCR	OS	K-M	7
W Qian	2018	China	NPC	48	28/20	I-IV	qRT-PCR	OS	K-M	8
Y-b Lu	2018	China	PC	72	50/22	I-IV	qRT-PCR	OS	K-M	8
K Yao	2018	China	CRC	185	129/56	I-IV	qRT-PCR	OS	HR/K-M	8
G-m Zheng	2018	China	CRC	90	51/39	I-IV	qRT-PCR	OS	HR/K-M	8
Y-c Niu	2017	China	SCLC	33	16/17	NA	qRT-PCR	OS	K-M	7
P-q Wang	2017	China	RCC (ccRCC)	203	100/103	I-IV	qRT-PCR	OS	HR/K-M	8
Y Wang	2017	China	OSA	44	30/14	I-IIA/IIB-III	qRT-PCR	OS	K-M	8
J Droop	2017	Germany	UC	106	NA	I-IV	qRT-PCR	OS/DFS	HR/K-M	8
L Zhao	2017	China	PC	34	18/16	I-IV	qRT-PCR	OS	K-M	8
G-q Yan	2017	China	OSCC	46	24/24	I-IV	qRT-PCR	OS	HR/K-M	8
J Zhu	2017	China	CC	59	30/29	I-IIA/IIB-IIIA	qRT-PCR	OS	K-M	8
Y Xu	2017	China	CCA	51	30/29	I-IV	qRT-PCR	OS	K-M	8
B Zeng	2017	China	CCA	102	NA	I-IV	qRT-PCR	OS/DFS	HR/K-M	7
D-f Gradia	2017	TCGA	BC (luminal B)	122	92/30	I-IV	RNA-seq	DFS	HR/K-M	5
D-f Gradia	2017	TCGA	BC (HER2-enriched)	56	14/42	I-IV	RNA-seq	DFS	HR/K-M	5
Z Baratieh	2017	TCGA	GBM	260	130/130	NA	RNA-seq	OS	K-M	5
D Liu	2017	China	NHL	108	61/47	I-IV	qRT-PCR	OS	HR/K-M	8
T Shen	2017	China	GC	48	35/13	I-IV	qRT-PCR	OS	K-M	8
J Li	2016	China	GBM	120	60/60	I-IV	qRT-PCR	OS	K-M	8
J-f Sun	2016	China	CRC	120	72/48	I-IV	qRT-PCR	OS	K-M	8
E Zhang	2016	China	GC	100	50/50	I-IV	qRT-PCR	OS	HR/K-M	8
L Jiang	2016	China	ESCC	218	109/109	I-IV	qRT-PCR	OS	HR/K-M	8
R Iliev	2016	Czech Republic	BLC	47	26/21	II-IV	qRT-PCR	OS	HR/K-M	7
P-c Lin	2016	China	NSCLC	89	31/58	I-IV	qRT-PCR	OS	K-M	8
J-m Tan	2015	China	BLC	54	27/27	I-IV	qRT-PCR	OS	K-M	7
B Ma	2015	China	OSA	76	41/35	I-III	qRT-PCR	OS/PFS	HR/K-M	8
E-b Zhang	2014	China	NSCLC	192	96/96	I-IV	qRT-PCR	OS	K-M	6

Abbreviations: AML: acute myeloid leukemia; BC: breast cancer; BLC: bladder cancer; CC: cervical cancer; CCA: cholangiocarcinoma; CRC: colorectal cancer; EC: endometrial carcinoma; ESCC: esophageal squamous cell carcinoma; GBM: glioblastoma; GC: gastric cancer; HCC: hepatocellular carcinoma; NHL: non-Hodgkin’s lymphoma; NPC: nasopharyngeal carcinoma; NSCLC: non-small-cell lung cancer; OC: ovarian cancer; OSA: osteosarcoma; OSCC: oral squamous cell carcinoma; PC: pancreatic carcinoma; PCa: prostate cancer; RCC: renal cell carcinoma; SCLC: small cell lung cancer; UC: urothelial carcinoma.